Evidence map›Paper›PMID 35534298›Full record

ArticleAtherosclerosis2022

The effect of LPA Thr3888Pro on lipoprotein(a) and coronary artery disease is modified by the LPA KIV-2 variant 4925G>A.

Rebecca Grüneis, Claudia Lamina, Silvia Di Maio, Sebastian Schönherr, Peter Zoescher, Lukas Forer, Gertraud Streiter, Annette Peters, Christian Gieger, Anna Köttgen and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Atherosclerosis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Rebecca GrüneisInstitute of Genetic Epidemiology, Department of Genetics and Pharmacology, Medical University of Innsbruck, Austria.
Claudia LaminaInstitute of Genetic Epidemiology, Department of Genetics and Pharmacology, Medical University of Innsbruck, Austria.
Silvia Di MaioInstitute of Genetic Epidemiology, Department of Genetics and Pharmacology, Medical University of Innsbruck, Austria.
Sebastian SchönherrInstitute of Genetic Epidemiology, Department of Genetics and Pharmacology, Medical University of Innsbruck, Austria.
Peter ZoescherInstitute of Genetic Epidemiology, Department of Genetics and Pharmacology, Medical University of Innsbruck, Austria.
Lukas ForerInstitute of Genetic Epidemiology, Department of Genetics and Pharmacology, Medical University of Innsbruck, Austria.
Gertraud StreiterInstitute of Genetic Epidemiology, Department of Genetics and Pharmacology, Medical University of Innsbruck, Austria.
Annette PetersGerman Center for Diabetes Research (DZD), München-Neuherberg, Germany; Institute of Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany.
Christian GiegerGerman Center for Diabetes Research (DZD), München-Neuherberg, Germany; Institute of Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany; Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.
Anna KöttgenInstitute of Genetic Epidemiology, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany and German Chronic Kidney Disease Study, Germany.
Florian KronenbergInstitute of Genetic Epidemiology, Department of Genetics and Pharmacology, Medical University of Innsbruck, Austria.
Stefan CoassinInstitute of Genetic Epidemiology, Department of Genetics and Pharmacology, Medical University of Innsbruck, Austria. Electronic address: Stefan.Coassin@i-med.ac.at.
Innsbruck Medical University · ATHelmholtz Zentrum München · DEUniversity of Freiburg · DE

Funding

Austrian Science Fund FWF P 31458Medical Research Council MC_PC_17228Medical Research Council MC_QA137853
6 · The paper itself

Abstract

BACKGROUND AND

aimsHigh lipoprotein(a) [Lp(a)] concentrations are associated with increased coronary artery disease (CAD) risk. Lp(a) is regulated mainly genetically by the LPA gene but involved genetic variants have not been fully elucidated. Improved understanding of the entanglements of genetic Lp(a) regulation may enhance genetic prediction of Lp(a) and CAD risk. We investigated an interaction between the well-known LPA missense SNP rs41272110 (known as Thr3888Pro) and the frequent LPA splicing mutation KIV-2 4925G>A.

methodsEffects on Lp(a) concentrations were investigated by multiple quantile regression in the German Chronic Kidney Disease (GCKD) study, KORA-F3 and KORA-F4 (n

resultsWe observed a significant SNP-SNP interaction in all studies (p = 1.26e-05 to 3.03e-04). In quantile regression analysis, rs41272110 as a predictor shows no impact on Lp(a) (β = -0.06 [-0.79; 0.68], p = 0.879), but in a joint model including both SNPs as predictors, rs41272110 is associated with markedly higher Lp(a) (β = +9.40 mg/dL [6.45; 12.34], p = 4.07e-10). Similarly, rs41272110 shows no effect on CAD in UKB (HR = 1.01 [0.97; 1.04], p = 0.731), while rs41272110 carriers not carrying 4925G>A show an increased CAD risk (HR = 1.10 [1.04; 1.16], p = 6.9e-04). This group corresponds to 4% of the population. Adjustment for apolipoprotein(a) isoforms further modified the effect estimates markedly.

conclusionsThis work emphasizes the complexity of the genetic regulation of Lp(a) and the importance to account for genetic subgroups in Lp(a) association studies and when interpreting genetic cardiovascular risk profiles.

Indexed as

Coronary Artery DiseaseLipoprotein(a)Apolipoproteins AHumansPolymorphism, Single NucleotideRisk FactorsApolipoproteins ALipoprotein(a)Apolipoprotein(a)Coronary artery diseaseKringle IV-2 repeatLipoprotein(a)MutationSNP interaction

Identifiers

PMID35534298
PMCPMC7613586
OpenAlexW4224536444

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.